For Visitors

ExciPerience – 9. & 10. March 2022

Your participation in ExciPerience gives you three main opportunities:


You have a lot of possibilities for interaction – with people of the pharma excipients community from all over the world


You expand and broaden your pharmaceutical excipients knowledge and get a chance to meet new suppliers and customers


You get to know innovative product solutions for various formulation challenges and new technical possibilities

Meet new interesting people, your friends and acquaintances you missed meeting personally during the last year!

Confirmed speakers 2022

Nikoletta Fotaki's research and activities are focused on the prediction of drug absorption through the oral and non oral (i.e.inhalation, subcutaneous) route. She is working on the development of in vitro screening tools and associated software for predicting absorption and in vivo performance (in normal populations and in special populations; i.e. paediatrics), on in vitro dissolution/ biorelevant dissolution methods, on dissolution imaging, on formulation development, design and interpretation of bioavailability and bioequivalency studies, on safety of drugs (pharmacokinetics and toxicokinetics), on the appropriate use of animal models for the prediction of absorption, on the reduction/ refinement/ replacement of animal experimentation and on the development of in vitro-in vivo correlations and relations and on Physiologically Based Pharmacokinetic (PBPK) Modeling.

Dr. Nikoletta Fotaki, Pharm, MSc, FAAPS


David R. Schoneker is currently an independent consultant and the President and Owner of Black Diamond Regulatory Consulting, LLC, a consulting firm specializing in providing regulatory and quality consulting for the pharmaceutical, dietary supplement, food and related industries.

With over 43 years of experience working in these areas, he has developed strong networks with regulatory agencies and pharmacopeias around the world.

Dave Schoneker, M.Sc.


Christian Lübbert studied chemical engineering at TU Dortmund University and finished his PhD in 2018. During his PhD, he successfully predicted the long-term stability of hundreds of pharmaceutical formulations via thermodynamic modeling. He developed methods to measure and to predict unwanted changes in ASDs during long-term storage, e.g. amorphous phase separation and crystallization. 

His work was awarded as the best German PhD thesis in thermodynamics in 2018. Moreover, he received the TU Dortmund PhD award.

Dr. Christian Lübbert

Predictive development / In-silico development

In November 2009, Dr Liu joined the University of Hertfordshire as a Lecturer in Clinical Pharmaceutics. Her research interests focus on developing patient-centric medicines for children and older adults. She is a co-chair of the Age-Related Medicines Focus Group in Academy of Pharmaceutical Sciences of Great Britain (APSGB), and is involved in the work of European Paediatric Formulation Initiative (EuPFI) and the Patient Centric Medicine (PaCeMe) initiative.

She has published her work in over 25 peer reviewed journal articles and is the Founder and Executive Director of Fluid Pharma Ltd. 

Prof. Dr. Fang Liu

Paediatric formulations

Maxim Puchkov became the CEO of the Center for Innovation in Computer-Aided Pharmaceutics (CINCAP GmbH) in 2007 and in 2010 he joined the group of Prof. Dr. Jörg Huwyler as scientific collaborator.

His scientific interests are focused on massively-parallel computational models for a design of pharmaceutical formulations; discrete element models for design, understanding, and optimization of pharmaceutical processes and unit operations; interactive and process-oriented computer tools and simulators for advanced teaching and training of industrial unit operations.

Dr. Maxim Puchkov

In-silico formulation design

These were the speakers 2021

Sandra Klein is currently professor of biopharmaceutics and pharmaceutical technology. Prof. Klein is a board member of APV, an EuPFI associate and a member of AAPS, CRS, DPhG. Moreover, she is a member of the editorial board of several scientific journals.

Her current research is focused on developing predictive dissolution methods and dosage forms for special patient groups, particularly the paediatric and geriatric population.

Prof. Dr. phil. nat. Sandra Klein


David R. Schoneker is currently an independent consultant and the President and Owner of Black Diamond Regulatory Consulting, LLC, a consulting firm specializing in providing regulatory and quality consulting for the pharmaceutical, dietary supplement, food and related industries.

With over 42 years of experience working in these areas, he has developed strong networks with regulatory agencies and pharmacopeias around the world.

Dave Schoneker, M.Sc.


Jennifer Cain Birkmose is Vice President, Global Head of Patient Access and Community Engagement of sobi - Swedish Orphan Biovitrum AB (publ). Moreover, she is Member of the Board of Directors at Medicines for Malaria Venture.

Her professional experience and personal motivations are driven by an interest in advancing the health of populations globally. She sees the advancement of public health and improving the quality, efficiency and effectiveness of health care systems as intertwined.

Jennifer Cain Birkmose, M.Sc.


Bahijja Raimi-Abraham is a pharmacist, Lecturer in Pharmaceutics at King’s College London, Founder and Academic Lead of King’s College London Fight the Fakes. She leads her research group “The Raimi-Abraham Group” and is a board member for the Academy of Pharmaceutical Sciences (APS).

Her research to date has been in pharmaceutical materials and innovative manufacture. More recently she has focused her research efforts within the therapeutic and drug development aspects of malaria.

Bahijja Raimi-Abraham, PhD

Drug Delivery

Alvaro Goyanes is the Development Director and lead project researcher at FabRx. Moreover, he is lecturer at USC and UCL and a highly cited researcher by Clarivate Web of Science for the 2nd year in a row!

Alvaro holds a PhD in pharmaceutical technology and was one of the first researchers assessing opportunities of 3D printing using Fused Deposition Modeling (FDM) to manufacture oral dosage forms and medical devices.

Alvaro Goyanes, PhD

3D Printing

Chris Moreton is Vice President of FinnBrit Consulting and currently a member of the Excipient Monographs 2 Expert committee of the United States’ Pharmacopeia and also on the Board of the IPEC Foundation.

He has more than 30 years experience in the development of new drug candidates and generic drugs, in many therapeutic areas, using different dosage forms and routes of administration. But also in QA/QC and Technical Support in excipients and drug delivery.

Chris Moreton, PhD

Excipients QbD

Hans Platteeuw started in 2005 Avivia BV, an independent company specialized in pharmaceutical product development with a specific expertise in the development and intellectual property protection of specialty generics products and in guiding the initial finished product development from phase I all the way up to phase III and commercial production.

His specialty is translating lead compounds into pharmaceutical products that can be made cost effectively and put on a shelf in a pharmacy.

Hans Platteeuw, M.Sc.


Allison Labriola is a Senior Technical Sales Representative for JRS, specializing in Vivacoat. She supports film coatings from a sales and technical perspective throughout North America.

Allison has an extensive background in pharmaceutical coating and tablet formulation thanks to over 15 years of experience working in sales, technical, and manufacturing roles.

Allison Labriola, B.A.


Raphael Janousek works as a project manager at BIOGRUND GmbH. In his role as a project manager he is part of the global sales team and responsible for the DACH and Scandinavian market.

He holds a master’s degree in Bio- and Pharmaceutical Analysis and a Dr. in Chemistry. With his strong scientific background he consults pharmaceutical and nutraceutical companies in customized film coating, tableting and coloring formulation.

Raphael Janousek, Dr. rer. nat.

Project Manager for excipient premixes

Ajaz Hussain is the President of The National Institute for Pharmaecuetical Technology & Education. His background includes decades of experience in industry, US FDA, and in academic research and teaching to include a number of high-level corporate leadership positions.

His career at US FDA spanned 10 years, where he served as the Deputy Director of the Office of Pharmaceutical Science (OPS) in the Center for Drug Evaluation and Research (CDER) and a “peer reviewed” Senior Biomedical Research position in the US Government Service.

Ajaz S. Hussain, PhD


Dario Dornbierer studied pharmaceutical sciences at the ETH Zurich and holds a PhD in the field of sleep pharmacology. During his current bio-entrepreneurial PostDoc position at the University Hospital of Psychiatry in Zurich, he investigates the clinical potential of illicit drugs for the treatment of psychiatric disorders, such as GHB and Ayahuasca.

Moreover, he is continuously driving the research on how to optimize psychiatric drug therapies applying cutting-edge pharmaceutical technologies. Dario acts as Co-founder and CSO of Galventa.

Dario Dornbierer, PhD

Galventa / University Hospital of Psychiatry in Zurich

Sascha Fritsche, CFA, has an MA in banking and finance from the University of St. Gallen (HSG). During several years he gathered insights into strategy consulting and banking while working for Helbling Management Consulting, Credit Suisse and Nomura. 

In the past eight years, he acted as the CFO in an ETH-spin-off, which he accompanied on the journey from very few to over 200 employees. Sascha acts as Co-founder and CEO of Galventa.

Sascha Fritsche, M.A.


Ana Gutierrez has a pharmaceutical engineering degree from the National Polytechnic Institute and a Masters in Pharmaceutical Sciences from the Metropolitan Autonomous University. She gained considerable industrial experience through positions as manufacturing technology scientist at Bristol Myers Squibb in Mexico, where she also held an Assistant Professor position at the Pharmacy School at the Metropolitan Autonomous University.

At Gattefossé Ana is responsible for providing formulation and process development technical support and delivering internal and external training programs for customers and European universities.

Ana Gutierrez, M.Sc.


Tomas Skrinskas has been at the leading edge of transformative health care technologies including computer assisted surgery, surgical robotics and genetic nanomedicines for over 15 years, 

His career began with research and engineering which provided a strong foundation for the business development and operations roles that followed. Tomas founded Ascension Sciences, a R&D laboratory focused on nanoparticle development for cannabinoid products and therapeutics, in January 2019.

Tomas Skrinskas, MBME, MBA

Ascension Sciences

With nearly 30 years of experience in the Pharmaceutical and Nutritional industries, Larry currently is the Pharmaceutical / Nutraceutical Sales Manager at BENEO, Inc. in North America.

Larry started his career in the laboratory specializing in the development of aqueous and enteric film coating systems along with direct compression calcium and oyster shell products for solid dosage (tablet) applications at CHR Hansen formerly Crompton & Knowles ITC.

In his near 30 year career; Larry has worked not only for manufacturers of high quality excipients i.e.: Sensient Pharmaceuticals formerly Warner Jenkinson and JM Huber Corporation, he also worked for over 6 years at IMCD US LLC formerly Mutchler, Inc. whom distributed a large portfolio of excipients from manufacturers around the world.

Larry Walsh, Jr., B.A.

BENEO / galenIQ

Cross-functional team lead covering aspects of novel product and process development, regulatory strategy, intellectual property, and market assessment. 

Member of the innovation teams responsible for development and regulatory entrée of 3D printed products in multiple medical fields. Over twenty years of experience applying 3D printing technology to pharmaceuticals and medical devices.

Familiar with startup to commercial stage corporate environment, ranging from a few people to over 100. Significant interaction with legal counsel across specialties, including FDA law, patent & trademark law, and contract law.

Tom West, M.Sc.


Pavel Abdulkin is the Chief Commercial Officer at Microcaps AG. He has over 10 years experience in development of nano- and microencapsulation techniques to enable controlled release and targeted delivery applications across pharmaceutical and nutraceutical industries.

At Microcaps Pavel is responsible for development and implementation of the commercial strategy as well as customer outreach and strategic partnerships.

Pavel Abdulkin, PhD


Dominik Witzigmann is an award-winning investigator working at the forefront of lipid nanoparticle research, the fastest growing RNA delivery technology. Within the NanoMedicines Innovation Network (NMIN), he leads the NanoCore legacy initative to facilitate the development, characterization and formulation of translational nanomedicines.

Dominik obtained his Ph.D. in Pharmaceutical Sciences, and he has a proven track record in nanomedicine technologies enabling tissue and cell specific drug and gene delivery. He serves as a board member of the Gene Delivery and Genome Editing focus group of the Controlled Release Society.

Dominik Witzigmann, PhD

NanoMedicines Innovation Network, University of British Columbia

Dr. Tomaž Einfalt is a project leader at the University of Basel. During the last 4 years he has been working on translating exosomal and lipid nanoparticle technologies from bench to bedside. 

His work was featured at the Swiss Innovation Challenge and lead to key industry collaborations looking into translation of inventions into clinical products. 

Dr. Tomaž Einfalt

University of Basel

Krizia holds a PhD in Chemical and Biochemical Engineering from Rutgers University in New Jersey, USA and more than 10 years of experience in the pharmaceutical industry. Her technical approaches include formulation optimization, continuous manufacturing processes for solid oral dosage products, Process Analytical Technology (PAT) and spectroscopy for real-time measurements of critical quality attributes.

Her work extends to global companies including Pfizer, Bristol-Myers Squibb, AstraZeneca and Eli-Lilly. Krizia has published articles and chapters on innovative formulations, new drug delivery methods, process engineering and controls, and the implementation and validation of PAT tools.

Krizia M. Karry, Ph.D.

BASF Pharma Solutions

Nina Hauschildt is a Principal Scientist in the Formulation & Application Services at Evonik Operations GmbH. In this role she gives technical support to customers in North and Western Europe with a focus on excipients for oral drug delivery. 

She holds a bachelor degree in pharmaceutical engineering and a green belt certificate. Based on her long experience in formulating complex oral dosage forms using functional excipients she is a frequently used source for formulation and process challenges in all application areas. 

Nina Hauschildt

Evonik Operations GmbH

Lise Vandevivere is a pharmacist and currently a PhD researcher at Ghent University. She is a member of the Laboratory of Pharmaceutical Technology supervised by Prof. Dr. Chris Vervaet.

Her research is focussing on formulation development using the fully continuous ConsiGma-25 production line.

Lise Vandevivere

Ghent University

Be assured: We will find very interesting topics and speakers to present each field at ExciPerience 2022!

What you can do at ExciPerience?

Interact with interesting people! You will have various possibilities for direct conversation. In addition you can get to know new people in an easy and nice way. Be curious!

We offer classic presentations but also formats as panels and some new formats as well. Be excited!

Get to know innovative product solutions from our industry partners. You can arrange meetings in advance, you can address your specific formulation challenge – You will be helped!

Main Topics

3D Printing

Continuous Manufacturing

Drug Delivery

Platinum Partner 2021

Platinum Partner Biogrund


BIOGRUND has been the specialist for the homogeneous mixing of excipients and carriers. With locations in Germany, Switzerland, America and Russia, they support the food supplement and pharmaceutical industry in the development, formulation and production of solid oral dosage forms. The tailor-made and ready-to-use special powder mixtures for film coatings, sugar-coatings, colorings and tableting enable optimum results in a short time. Customized film coating systems for fast, enteric and sustained release. Furthermore, premixed tableting excipients like binders, lubricants, retard release compositions and pigment blends deliver new possibilities to improve your production processes. 

Easy, fast and reliable!

Gold Partners 2021

Gold Partner galenIQ


galenIQTM from BENEO is a highly functional filler and binder, characterized by its ease of use and applicability to a wide range of solid and liquid dosage forms such as tablets, sachets, lozenges and syrups. It is manufactured under cGMP conditions according to IPEC-PQG requirements for pharmaceutical excipients and complies with the current Ph. Eur., BP, USP-NF and JP monographs for Isomalt.

galenIQTM is known for its outstanding taste properties and makes medicine taste great.

Gold Partner APRECIA


Aprecia is the global leader in commercial-scale 3DP for pharmaceutical manufacturing technology. We’re committed to creating new solutions for unmet healthcare needs by developing pharma-ready innovations and complementary technology platforms that enable patient-centric products and help take medicine to its fullest potential.

The future of pharmaceutical manufacturing is happening here.

Gold Partner Gattefossé


Gattefossé is a leading provider of lipid excipients and formulation solutions to healthcare industries worldwide. We are committed to delivering high quality excipients, technical support and inspiring your formulations. With an in-depth knowledge of lipid excipient physicochemical and functional properties, we are your reliable partner for drug development.

We develop, produce and market first-class products and services of a consistently high quality.

Gold Partner BASF


At BASF, we are using our expertise in polymer chemistry to ensure successful formulation of pharmaceutical medicines, by providing excipients of outstanding quality and performance. From drug discovery, into development, through clinical trials, to long-term commercial supply, whatever your excipient challenge, we have a specialist to support you every step of the way.

We provide more than products. We provide several platform solutions.

Gold Partner Evonik


Evonik Health Care partners with the world’s pharmaceutical, medical device and nutraceutical companies to transform complexity into value.

Our core competencies allow us to specialize where you need us most, ensuring access to the right people, products and capabilities to streamline your path to market and improve commercial performance.

Your Competitive Advantage!

Silver Partners 2021

Logo ingredientpharm

Cooperations 2021

Qualit-E Logo transparent

Ready for a different event experience?

Share This